老年人接种三剂mRNA新冠疫苗后体液与细胞免疫应答的决定因素
挪威公共卫生研究院建立65-80岁纵向队列(4551人),其中部分亚组检测接种前及两剂、三剂后体液(n=299)和细胞(n=90)免疫应答。衰弱未与免疫应答受损相关。
核心结论
- 多数老年人包括有共病者,两剂疫苗后产生良好血清学和细胞应答,三剂后进一步改善,尤其异源加强后。
- 衰弱未与免疫应答受损相关,但高血压可能提示即使三剂后疫苗反应性降低。
研究设计与样本
- 挪威公共卫生研究院建立65-80岁成年人纵向队列,共招募4551人。
- 亚组检测接种前及两剂、三剂后体液(n=299)和细胞(n=90)免疫应答,健康、感染和接种信息来自问卷和国家健康登记。
主要发现
- Spike特异性CD4和CD8 T细胞应答在接种后高度异质,并对alpha、delta和omicron变异株有反应。
- 季节性冠状病毒细胞应答在SARS-CoV-2接种后升高。
临床怎么用
- 纵向采样识别的个体差异有助于更好预测疫苗应答变异性,可帮助指导后续剂次需求及接种时机的未来政策。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older age is associated with poorer outcomes to COVID-19 infection. The Norwegian Institute of Public Health established a longitudinal cohort of adults aged 65-80 years to study the effects of the COVID-19 pandemic. Here we describe the characteristics of the cohort in general, and specifically the immune responses at baseline and after primary and booster vaccination in a subset of longitudinal blood samples, and the epidemiological factors affecting these responses. METHODS: 4551 participants were recruited, with humoral (n=299) and cellular (n=90) responses measured before vaccination and after two and three vaccine doses. Information on general health, infections, and vaccinations were obtained from questionnaires and national health registries. FINDINGS: Half of the participants had a chronic condition. 849 (18·7%) of 4551 were prefrail and 184 (4%) of 4551 were frail. 483 (10·6%) of 4551 had general activity limitations (scored with the Global Activity Limitation Index). After dose two, 295 (98·7%) of 299 participants were seropositive for anti-receptor binding domain IgG, and 210 (100%) of 210 participants after dose three. Spike-specific CD4 and CD8 T cell responses showed high heterogeneity after vaccination and responded to the alpha (B.1.1.7), delta (B.1.617.2), and omicron (B.1.1.529 or BA.1) variants of concern. Cellular responses to seasonal coronaviruses increased after SARS-CoV-2 vaccination. Heterologous prime boosting with mRNA vaccines was associated with the highest antibody (p=0·019) and CD4 T cell responses (p=0·003), and hypertension with lower antibody levels after three doses (p=0·04). INTERPRETATION: Most older adults, including those with comorbidities, generated good serological and cellular responses after two vaccine doses. Responses further improved after three doses, particularly after heterologous boosting. Vaccination also generated cross-reactive T cells against variants of concern and seasonal coronaviruses. Frailty was not associated with impaired immune responses, but hypertension might indicate reduced responsiveness to vaccines even after three doses. Individual differences identified through longitudinal sampling enables better prediction of the variability of vaccine responses, which can help guide future policy on the need for subsequent doses and their timing. FUNDING: Norwegian Institute of Public Health, Norwegian Ministry of Health, Research Council of Norway, and Coalition for Epidemic Preparedness Innovations.
引用
- Ravussin A, Robertson AH, Wolf AS, et al. Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study. Lancet Healthy Longev. 2023. PMID: 37148891. doi:10.1016/S2666-7568(23)00055-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。